阿德福韦酯治疗慢性乙型肝炎疗效观察

    The clinical efficacy of adefovir on chronic hepatitis B

    • 摘要: 目的:观察阿德福韦酯治疗慢性乙型肝炎的疗效。方法:34例慢性乙型肝炎患者口服阿德福韦酯,每次10 mg,每天1次,每3个月检测1次HBV DNA、肝功能及乙肝血清标志物。结果:治疗12个月时HBV DNA阴转17例,阴转率50%,其中HBV DNA<107拷贝/ml,阴转率为66.7%而HBV DNA ≥ 107拷贝/ml,阴转率为23.0%,差异有统计学意义(P=0.032);ALT<2倍正常值,阴转1/5例,而ALT>2倍正常值,阴转率为71.4%,差异无统计学意义(P=0.111),HBV DNA阴转率与乙肝血清标志物模式无明显关系(P>0.05)。结论:阿德福韦酯对低病毒载量的患者HBV DNA阴转率较高。

       

      Abstract: Objective:To observe antiviral efficacy of adefovir on chronic hepatitis B.Methods:Thirty-four cases of patients with chronic hepatitis B were administered oral dose of 10 mg of adefovir once daily.HBVDNA,hepatic function and the serum HBV markers were detected every three months.Results:After 12 months' treatment,HBVDNA converted to negative in 17 cases (50%).Among them,the HBVDNA negative conversion rate in patients whose HBVDNA was less than 107 cop/ml was 66.6%,and it was 23% in patients whose HBVDNA was ≥ 107 cop/ml.There was significant difference between these two kinds of patients (P<0.05).The HBVDNA negative conversion rate in patients whose ALT was less than two folds of normal value was 20%,and it was 71.4% in patients whose ALT was more than two folds of normal value.There was also significant difference between these two kinds of patients (P<0.05).There no correlation between HBVDNA negatives conversion rate and the mode of hepatitis B serum markers (P>0.05).Conclusions:Adefovir is effective in HBVDNA negative conversion rate for the patients with low HBV load and high ALT levels.

       

    /

    返回文章
    返回